Literature DB >> 8549764

Molecular cloning of mouse epiregulin, a novel epidermal growth factor-related protein, expressed in the early stage of development.

H Toyoda1, T Komurasaki, Y Ikeda, M Yoshimoto, S Morimoto.   

Abstract

A cDNA clone encoding a novel epidermal growth factor (EGF)-related growth regulator, epiregulin, was isolated from a cDNA library prepared from a mouse fibroblast-derived tumor cell line, NIH3T3/clone T7. The predicted amino acid sequence revealed that the purified epiregulin peptide of 46-amino acids was synthesized as an internal segment of a 162-amino acid putative transmembrane precursor. The structural organization was similar to that of TGF-alpha precursor among the members of the EGF family. Although epiregulin transcript was not detected in several adult normal tissues by Northern blot analysis, approximately 4.8-kb transcript was present in 7-day-old mouse embryo and then diminished to very low or undetectable levels. Our results suggest that epiregulin may play an important role in the regulation of epithelial cell growth during early development.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8549764     DOI: 10.1016/0014-5793(95)01403-9

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  16 in total

1.  Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that binds and activates ErbB4.

Authors:  D Zhang; M X Sliwkowski; M Mark; G Frantz; R Akita; Y Sun; K Hillan; C Crowley; J Brush; P J Godowski
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

2.  Epiregulin induces leptin secretion and energy expenditure in high-fat diet-fed mice.

Authors:  Rumana Yasmeen; Qiwen Shen; Aejin Lee; Jacob H Leung; Devan Kowdley; David J DiSilvestro; Lu Xu; Kefeng Yang; Andrei Maiseyeu; Naresh C Bal; Muthu Periasamy; Paolo Fadda; Ouliana Ziouzenkova
Journal:  J Endocrinol       Date:  2018-12-01       Impact factor: 4.286

3.  Two Microplitis demolitor polydnavirus mRNAs expressed in hemocytes of Pseudoplusia includens contain a common cysteine-rich domain.

Authors:  M R Strand; R A Witherell; D Trudeau
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

Review 4.  Epiregulin: roles in normal physiology and cancer.

Authors:  David J Riese; Richard L Cullum
Journal:  Semin Cell Dev Biol       Date:  2014-03-12       Impact factor: 7.727

5.  Mammary tumorigenesis induced by fibroblast growth factor receptor 1 requires activation of the epidermal growth factor receptor.

Authors:  Lindsey K Bade; Jodi E Goldberg; Hazel A Dehut; Majken K Hall; Kathryn L Schwertfeger
Journal:  J Cell Sci       Date:  2011-08-24       Impact factor: 5.285

Review 6.  Emerging therapeutic targets in schwannomas and other merlin-deficient tumors.

Authors:  Sylwia Ammoun; C Oliver Hanemann
Journal:  Nat Rev Neurol       Date:  2011-06-07       Impact factor: 42.937

7.  Epiregulin is a potent vascular smooth muscle cell-derived mitogen induced by angiotensin II, endothelin-1, and thrombin.

Authors:  D S Taylor; X Cheng; J E Pawlowski; A R Wallace; P Ferrer; C J Molloy
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

8.  Mesenchymal-epithelial interactions involving epiregulin in tuberous sclerosis complex hamartomas.

Authors:  Shaowei Li; Fumiko Takeuchi; Ji-An Wang; Qingyuan Fan; Toshi Komurasaki; Eric M Billings; Gustavo Pacheco-Rodriguez; Joel Moss; Thomas N Darling
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-21       Impact factor: 11.205

9.  Epiregulin is not essential for development of intestinal tumors but is required for protection from intestinal damage.

Authors:  Daekee Lee; R Scott Pearsall; Sanjoy Das; Sudhansu K Dey; Virginia L Godfrey; David W Threadgill
Journal:  Mol Cell Biol       Date:  2004-10       Impact factor: 4.272

10.  Transcriptomic analysis of pathways regulated by toll-like receptor 4 in a murine model of chronic pulmonary inflammation and carcinogenesis.

Authors:  Alison K Bauer; Jennifer Fostel; Laura M Degraff; Elizabeth A Rondini; Christopher Walker; Sherry F Grissom; Julie Foley; Steven R Kleeberger
Journal:  Mol Cancer       Date:  2009-11-19       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.